Clinical Trial Update: Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 as monotherapy or in combination with an an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature B-cell Malignancies

Drugs mentioned

• Anti-CD20 monoclonal antibody
• ICP-248

Snippet

Sponsor: InnoCare Pharma Inc. | Conditions: Mature B-cell Malignancies | Phase 1 | Status: RECRUITING